X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will used to advance the clinical development of Aileron’s lead product candidate, LTI-03. Currently, it is being evaluated in an early-stage clinical trial for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $40.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 03, 2024
Details:
The net proceeds will be used to advance the development of LTI-03, a peptide representing an important region of the Caveolin 1 (Cav1) protein, for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Titan Partners Group
Deal Size: $4.6 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 01, 2024
Details:
LTI-03 is a novel, Caveolin-1-related peptide that addresses both inhibition of pro-fibrotic signaling and survival of critical epithelial cells. It is being developed for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 01, 2024
Details:
The acquisition includes multiple clinical stage, orphan pulmonary disease candidates, including LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis (IPF).
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Recipient: Lung Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 31, 2023
Details:
Aileron intends to use the proceeds primarily to complete the ongoing Phase 1b clinical study of LTI-03, a Caveolin-1-related peptide in development for the treatment of idiopathic pulmonary fibrosis.
Lead Product(s): LTI-03
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: LTI-03
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Clear Street LLC
Deal Size: $18.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement October 31, 2023
Details:
ALRN-6924 is an MDM2/MDMX inhibitor that leverages Aileron’s proprietary peptide drug technology. The primary endpoint of the Phase 1b open-label trial was duration and incidence of severe neutropenia in cycle 1.
Lead Product(s): ALRN-6924
Therapeutic Area: Dermatology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 21, 2023
Details:
The primary endpoints are duration and incidence of severe neutropenia (Grade 4) in cycle 1. Secondary endpoints include the chemoprotective effect of ALRN-6924 on chemotherapy-induced alopecia, as well as other hematologic and non-hematologic toxicities.
Lead Product(s): ALRN-6924
Therapeutic Area: Dermatology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 30, 2022
Details:
Enhancements to protocol, informed by recent ALRN-6924 data, are designed to improve the opportunity to demonstrate protection against chemotherapy-induced severe neutropenia, alopecia (hair loss) and potentially other toxicities in patients with p53-mutated breast cancer.
Lead Product(s): ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 01, 2022
Details:
ALRN-6924, first-in-class MDM2/MDMX dual inhibitor, is designed to activate p53, which in turn upregulates p21, a known inhibitor of the cell replication cycle. ALRN-6924 is the only reported chemoprotective agent in clinical development to employ a biomarker strategy.
Lead Product(s): ALRN-6924,Carboplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2022
Details:
Aileron is developing ALRN-6924 to protect patients with p53 mutated cancers against chemotherapy-induced bone marrow toxicities and other toxicities.
Lead Product(s): ALRN-6924,Doxorubicin Hydrochloride,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ALRN-6924
Highest Development Status: Phase IProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
